Jorge E Romaguera

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
    Madhav Desai
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Hematol Oncol 6:55. 2013
  2. ncbi request reprint High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    Jorge E Romaguera
    Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:7013-23. 2005
  3. doi request reprint Mantle cell lymphoma: Frontline and salvage therapy
    Jorge E Romaguera
    Department of Lymphoma Myeloma, Unit 429, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Hematol Malig Rep 3:204-9. 2008
  4. ncbi request reprint Lymphoma of the colon
    Jorge Romaguera
    University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Gastroenterol 21:80-4. 2005
  5. doi request reprint Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
    Br J Haematol 151:47-53. 2010
  6. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
  7. doi request reprint Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine
    Kedar V Inamdar
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:4727-36. 2009
  8. ncbi request reprint A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma
    Chul S Ha
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 63:188-93. 2005
  9. ncbi request reprint International prognostic index-based outcomes for diffuse large B-cell lymphomas
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:3083-8. 2002
  10. ncbi request reprint Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
    J Clin Oncol 23:667-75. 2005

Detail Information

Publications55

  1. pmc Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
    Madhav Desai
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Hematol Oncol 6:55. 2013
    ..This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas. ..
  2. ncbi request reprint High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    Jorge E Romaguera
    Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:7013-23. 2005
    ..To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL)...
  3. doi request reprint Mantle cell lymphoma: Frontline and salvage therapy
    Jorge E Romaguera
    Department of Lymphoma Myeloma, Unit 429, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Hematol Malig Rep 3:204-9. 2008
    ..New insights into resistance pathways and new drugs created to inhibit them offer great promise in the treatment of newly diagnosed and previously treated MCL...
  4. ncbi request reprint Lymphoma of the colon
    Jorge Romaguera
    University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Gastroenterol 21:80-4. 2005
    ..Emphasis is on new entities such as mantle cell (MCL) and marginal zone (MZL) lymphomas. Presenting symptoms and signs are described where applicable and treatment and prognosis are covered briefly...
  5. doi request reprint Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
    Br J Haematol 151:47-53. 2010
    ..In particular, there was no pulmonary or neurological dose-limiting toxicity, showing that bortezomib can be safely combined with R-HyperCVAD and R-M/A...
  6. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  7. doi request reprint Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine
    Kedar V Inamdar
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:4727-36. 2009
    ..However, the clinical significance of eIF4E expression in MCL is unknown...
  8. ncbi request reprint A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma
    Chul S Ha
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 63:188-93. 2005
    ..MR was defined as disappearance of t(14;18) (q32;q21) amplified by polymerase chain reaction (PCR)...
  9. ncbi request reprint International prognostic index-based outcomes for diffuse large B-cell lymphomas
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:3083-8. 2002
    ..We present the results of doxorubicin-based chemotherapy with or without involved-field radiotherapy for patients with diffuse large B-cell lymphoma (DLBCL) according to the international prognostic index (IPI)...
  10. ncbi request reprint Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
    J Clin Oncol 23:667-75. 2005
    ..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma...
  11. ncbi request reprint Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
    ..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL...
  12. doi request reprint Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine
    Mar Garcia
    Department of Hematopathology, Box 72, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 115:1041-8. 2009
    ....
  13. doi request reprint Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 163:611-20. 2013
    ..In conclusion, R-HCVAD/R-MA is associated with excellent outcome in patients ≤45 years old. However, in patients >45 years old, R-HCVAD/R-MA is associated with unacceptable mortality rates. ..
  14. ncbi request reprint Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:586-91. 2003
    ..The impact of endoscopic assessment on the management of MCL patients is unknown...
  15. ncbi request reprint Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
    Apostolia M Tsimberidou
    Department of Lymphoma and Myeloma, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:4351-7. 2002
    ..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND...
  16. doi request reprint Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2734-41. 2008
    ....
  17. ncbi request reprint Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5432-8. 2004
    ..The purpose of this study was to evaluate the clinical activity and toxicity of recombinant human Interleukin (IL)-12 in patients with relapsed and refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)...
  18. ncbi request reprint Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  19. ncbi request reprint Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas
    Hoon K Lee
    Department of Radiation Oncology, Box 97, M D Anderson Cancer Center, 1515 Holcombe Blvd, University of Texas, Houston, TX 77030 4009, USA
    Leuk Lymphoma 43:1769-75. 2002
    ..Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses > or = 45 Gy, warrant investigation...
  20. ncbi request reprint CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome
    George Z Rassidakis
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1278-87. 2002
    ..Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD...
  21. doi request reprint Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort
    Tomasz P Srokowski
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:5067-73. 2011
    ..FND-R, a combination regimen of fludarabine, mitoxantrone, dexamethasone, and rituximab, has been shown to be an effective regimen for low-grade lymphomas...
  22. ncbi request reprint Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma
    Amar Safdar
    Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Infect Dis 194:1394-7. 2006
    ..For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine...
  23. doi request reprint Usefulness of flow cytometric immunophenotyping for bone marrow staging in patients with mantle cell lymphoma after therapy
    Wei Liu
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Am J Clin Pathol 137:634-40. 2012
    ..We conclude that FCI is more sensitive than morphologic examination of BM at the time of restaging in patients with MCL and that positivity by only FCI in BM often correlates with concurrent disease or subsequent relapse...
  24. pmc HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
    Richard J Jones
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:4140-9. 2011
    ..These findings provide a framework for translation of the rational combination of an HDM-2 and RNR inhibitor to the clinic for patients with relapsed wtp53 MCL...
  25. doi request reprint Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
    Victor Y Yazbeck
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Exp Hematol 36:443-50. 2008
    ..To investigate the mechanisms of antiproliferative effect induced by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in mantle cell lymphoma (MCL)...
  26. ncbi request reprint Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:345-53. 2005
    ....
  27. ncbi request reprint Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:574-80. 2004
    ..The aim of the current study was to assess the toxicity, safety, and efficacy of IFN-alpha combined with isotretinoin in patients with advanced, refractory lymphoid malignancies...
  28. ncbi request reprint Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:831-6. 2008
    ..The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL...
  29. doi request reprint Indolent peripheral T-cell lymphoma involving the gastrointestinal tract
    Vasiliki Leventaki
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA, 77030 Department of Pathology, St Jude Children s Research Hospital, Memphis, TN, USA, 38105 Electronic address
    Hum Pathol 45:421-6. 2014
    ..Rare cases of indolent peripheral T-cell lymphoma of the gastrointestinal tract have been previously described and need to be further characterized to avoid the use of aggressive chemotherapy. ..
  30. ncbi request reprint The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens
    Nancy P Caraway
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 105:110-8. 2005
    ....
  31. pmc Successful treatment of a free-moving abdominal mass with radiation therapy guided by cone-beam computed tomography: a case report
    Bouthaina Dabaja
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Med Case Reports 4:329. 2010
    ..Because tumors in the abdomen can change position, targeting these tumors for radiation therapy should be done with caution; use of daily image-guided radiation therapy is advised...
  32. ncbi request reprint Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:1818-21. 2006
    ..The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL...
  33. ncbi request reprint Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:481-5. 2006
    ..In these previously treated patients with NHL, a single dose of pegfilgrastim was effective in promoting neutrophil count recovery after paclitaxel and topotecan, and allowed patients to receive the next planned dose on time...
  34. pmc Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
    Peter McLaughlin
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, USA
    Blood 105:4573-5. 2005
    ..MDS with features classically associated with DNA-damaging agents can occur following therapy with FND, with or without rituximab, and IFN-alpha...
  35. ncbi request reprint Thalidomide for patients with recurrent lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1186-9. 2004
    ..However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease...
  36. ncbi request reprint A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
    Anas Younes
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:310-4. 2003
    ..Rituximab is used to primarily deplete normal B cells from HD lesions...
  37. ncbi request reprint Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit
    Bita Esmaeli
    Ophthalmology Section, Department of Plastic Surgery, Box 443, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Ophthalmol 120:1225-7. 2002
  38. ncbi request reprint Use of bortezomib in B-cell non-Hodgkin's lymphoma
    Michael Wang
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 6:983-91. 2006
    ..Mantle cell lymphoma was significantly more sensitive to bortezomib than other non-Hodgkin's lymphomas. Bortezomib may have far-reaching potential in the treatment of B-cell non-Hodgkin's lymphoma...
  39. doi request reprint Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 143:355-60. 2008
    ..In conclusion, oblimersen sodium can be safely combined with rituximab. The combination appears to be most beneficial in patients with indolent NHL and warrants further investigation in a large randomized trial...
  40. ncbi request reprint Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Eur J Cancer 42:2976-81. 2006
    ..Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule...
  41. ncbi request reprint Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas
    Luis Fayad
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 8:S57-62. 2007
    ..Toxicity is mainly hematologic and significant, but expected...
  42. doi request reprint Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen...
  43. doi request reprint Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
    Michael L Wang
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 369:507-16. 2013
    ..In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma...
  44. pmc Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
    Liang Zhang
    Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:3783-92. 2012
    ..Hence, our study identifies IL-6 as a key cytokine for MCL growth and survival and suggests that targeting the IL-6 pathway may be a novel way to improve the efficacy of chemotherapy in MCL patients...
  45. ncbi request reprint Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:601-5. 2002
    ....
  46. ncbi request reprint Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature
    Andres O Soriano
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 82:725-8. 2007
    ..A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease...
  47. ncbi request reprint Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings
    Jun Gu
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 17:553-60. 2004
    ....
  48. doi request reprint CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions
    Sanjay Gupta
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Hematol Oncol 28:75-81. 2010
    ....
  49. ncbi request reprint Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center
    Qi Liu
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1582-9. 2006
    ..Advanced-stage follicular lymphoma is considered incurable. The pace of improvements in treatment has been slow. This article analyzes five sequential cohorts of patients with stage IV follicular lymphoma treated between 1972 and 2002...
  50. ncbi request reprint Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas
    L Jeffrey Medeiros
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mod Pathol 15:556-64. 2002
    ..This method is rapid, can be applied to the analysis of fluid specimens, and obviates the need for time-consuming and laborious detection methods that are required by traditional semi-quantitative RT-PCR methods...
  51. doi request reprint A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2154-60. 2008
    ..To establish a severe combined immunodeficient (SCID)-hu in vivo mouse model of human primary mantle cell lymphoma (MCL) for the study of the biology and novel therapy of human MCL...
  52. ncbi request reprint Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:5455-62. 2007
    ..Cell apoptosis was induced mainly via activation of the AIF pathway. These results support the use of atiprimod as a potential agent in MCL chemotherapy...
  53. ncbi request reprint Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma
    John F Seymour
    Department of Haematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Clin Oncol 21:2115-22. 2003
    ..We investigated the potential for combined-modality therapy to increase the disease-free survival for such patients...
  54. ncbi request reprint Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond
    Yuhong Zhou
    Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
    Am J Hematol 83:144-9. 2008
    ..A Phase I/II study is ongoing to determine the maximum tolerated dose (MTD) and the efficacy of lenalidomide in combination with Rituximab for relapsed/refractory MCL. This review summarizes the latest and exciting advances in MCL...
  55. doi request reprint Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD
    Jatin J Shah
    Blood 112:2583; author reply 2583-4. 2008